Anesthesia Research
September 13, 2026
Camilla Teixeira Pinheiro Gusmão, Batuhan Özen, Marina Seixas Studart E Neves et al.
Background/Objectives: Fibromyalgia (FM) is a nociplastic pain syndrome characterized by chronic widespread pain, fatigue, sleep disturbance, cognitive dysfunction, and heightened sensitivity to somatic and environmental stimuli. Depressive symptoms and major depressive disorder (MDD) frequently co-occur with FM and are associated with greater disability, pain catastrophizing, sleep disruption,...
BMJ Open
July 13, 2026
Thomas D Meyer, Lauren N Vale, Maya Ibrahim et al.
Bipolar II disorder (BD-II) is characterised by hypomanic and depressive episodes with the latter tending to dominate the clinical course of the disorder, and they are often associated with suicidality. Despite available guideline-based recommendations for first-line pharmacological treatments, patient outcomes remain suboptimal, especially for those with chronic depression and suicidal...
European Psychiatry
April 1, 2025
Ilídio Oliveira, A. L. Stephany, M. L. Geremias et al.
Introduction Anxious depression (AxD) as an independent diagnostic has been controversial, with many suggesting it as a transient state and others highlighting evidence of a worse outcome, severity, and increased suicide risk. The International Classification of Diseases (ICD-11) lists a related concept under 6A73, Mixed depressive and anxiety disorder. Previous literature on ketamine’s...
Brain Stimulation
2024
Charles R Conway, Scott T Aaronson, Harold A Sackeim et al.
16 citations
RECOVER is a randomized sham-controlled trial of vagus nerve stimulation and the largest such trial conducted with a psychiatric neuromodulation intervention. To describe pre-implantation baseline clinical characteristics and treatment history of patients with unipolar, major depressive disorder (MDD), overall and as a function of exposure to interventional psychiatric treatments (INTs),...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
August 30, 2018
Manoj P Dandekar, Tao Peng, David D McPherson et al.
Similar to ketamine, xenon gas acts as a glutamatergic N-methyl-d-aspartate receptor antagonist, but devoid of propensity to cause untoward effects. Herein, we loaded xenon gas into a liposomal carrier called xenon-containing liposomes (Xe-liposome) for systemic delivery, and investigated its effect as an antidepressant and also analyzed synaptic biomarkers including brain-derived neurotrophic...
Acta Neuropsychiatrica
December 2010
Gislaine T Rezin, Cinara L Gonçalves, Juliana F Daufenbach et al.
Rezin GT, Gonçalves CL, Daufenbach JF, Carvalho-Silva M, Borges LS, Vieira JS, Hermani FV, Comim CM, Quevedo J, Streck EL. Effect of chronic administration of ketamine on the mitochondrial respiratory chain activity caused by chronic mild stress. Recently, we reported that mitochondrial respiratory chain complexes I, III and IV were inhibited in the cerebral cortex and cerebellum of rats...
Revista Brasileira de Psiquiatria
September 2009
Lara C Assis, Gislaine T Rezin, Clarissa M Comim et al.
Clinical findings suggest that ketamine may be used for the treatment of major depression. The present study aimed to compare behavioral effects and brain Creatine kinase activity in specific brain regions after administration of ketamine and imipramine in rats. Rats were acutely given ketamine or imipramine and antidepressant-like activity was assessed by the forced swimming test; Creatine...
Brain Research Bulletin
August 14, 2009
Gislaine T Rezin, Cinara L Gonçalves, Juliana F Daufenbach et al.
Modulation and dysfunction of the glutamatergic system seems to be involved in depression. Recently a renewed interest in the glutamatergic system as a treatment option for major depression emerged by the finding that the glutamate N-methyl-D-aspartate (NMDA) antagonist ketamine leads to a rapid improvement of depressive symptoms. Several works support the hypothesis that metabolism impairment...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
April 30, 2009
Lêda S B Garcia, Clarissa M Comim, Samira S Valvassori et al.
Several studies have supported the idea that ionotropic glutamate N-methyl-d-aspartate receptor (NMDA) is an important player in the etiology of psychopathologies, such as anxiety disorders and major depression. Additionally, studies have shown that ketamine induces antidepressant effects in humans as well as in rodents subjected to animal models of depression. In this context, the present...
Basic & Clinical Pharmacology & Toxicology
December 2008
Lêda S B Garcia, Clarissa M Comim, Samira S Valvassori et al.
A growing body of evidence has pointed to the blockade of the N-methyl-d-aspartate (NMDA) receptor signaling as a potential therapeutic target for the treatment of major depression. The present study was aimed to evaluate behavioural and molecular effects of the chronic treatment with ketamine and imipramine in rats. To this aim, rats were 14 days treated once a day with ketamine (5, 10 and 15...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 1, 2008
Lêda S B Garcia, Clarissa M Comim, Samira S Valvassori et al.
Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor. Clinical findings point to a rapid onset of action for ketamine on the treatment of major depression. Considering that classic antidepressants may take long-lasting time to exhibit their main therapeutic effects, the present study aims to compare the behavioral effects and the BDNF...